Mobile

Open, randomized, multinational phase IIIb trial evaluating the activity and safety of cetuximab as 250 mg/m² weekly and 500 mg/m² every two weeks maintenance therapy after platinum-based chemotherapy...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-004454-33

Open, randomized, multinational phase IIIb trial evaluating the activity and safety of cetuximab as 250 mg/m² weekly and 500 mg/m² every two weeks maintenance therapy after platinum-based chemotherapy in combination with cetuximab as first-line treatment for subjects with advanced non-small cell lung cancer (NSCLC)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Separate assessment of the activity of each cetuximab maintenance therapy (500 mg/m² every 2 weeks and 250 mg/m² every week) in terms of overall survival time from inclusion in the trial to death in subjects with advanced NSCLC who are free of progression after having received cetuximab in combination with a platinum doublet chemotherapy as first-line treatment.

Liens